European CHMP recommends precautionary suspension of ranitidine medicines in the EU

This is due to the presence of low levels of NDMA, classified as a probable human carcinogen. Although available data do not show ranitidine increases risk of cancer, and suggest any possible risk is likely very low, there are unresolved questions about the source of impurity.


European Medicines Agency